Triols

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

Retrieved on: 
Friday, June 25, 2021
Ophthalmology, Drugs, Health care, Prostaglandins, NicOx, Triols, Blindness, Bausch & Lomb, Glaucoma, Lomb, Ocular hypertension, Bausch Health

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates.
  • Now approved in 12 countries, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Argentina (2020), Mexico (2020), Hong Kong (2020) and Taiwan (2021).
  • It is also approved in Brazil, Colombia, Qatar, South Korea, Ukraine and the United Arab Emirates.
  • VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

Crude Glycerine Market Size Worth $1.26 Billion By 2028 | CAGR: 8.1%: Polaris Market Research

Retrieved on: 
Monday, April 26, 2021
Biofuels, Demulcents, Glycerol, Triols, Chemical substances, Matter, Chemistry

b'NEW YORK, April 26, 2021 /PRNewswire/ -- The global crude glycerine market size is expected to reach USD 1.26 billion by 2028 according to a new study conducted by Polaris Market Research.

Key Points: 
  • b'NEW YORK, April 26, 2021 /PRNewswire/ -- The global crude glycerine market size is expected to reach USD 1.26 billion by 2028 according to a new study conducted by Polaris Market Research.
  • the market isanticipated to register a CAGR of 8.1% from2021 2028.
  • Increasing industrialization globally and a rise in demand from wastewater treatment is anticipated to create lucrative opportunities in the crude glycerine market.
  • Feel Free To Ask Our Industry Experts At : https://www.polarismarketresearch.com/industry-analysis/crude-glycerine-...\nPolaris Market Research has segmented the crude glycerine market report on the basis of glycerol content, application, region:\nCrude Glycerine Glycerol Content Outlook (Revenue, USD Million, 2016 2028)\n'

Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone

Retrieved on: 
Tuesday, March 23, 2021
Chemical compounds, Organic compounds, Drugs, Prostaglandins, NicOx, Glaucoma, Triols, Cyclopropanes, Latanoprost, Intraocular pressure, Ocular hypertension

Mont Blanc is a 3-month multi-regional Phase 3 clinical trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1% versus latanoprost ophthalmic solution, 0.005%, for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Key Points: 
  • Mont Blanc is a 3-month multi-regional Phase 3 clinical trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1% versus latanoprost ophthalmic solution, 0.005%, for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • The Mont Blanc trial was initiated in the U.S. in June 2020 with an initial adaptive design portion wherein the highest dose of NCX 470 tested in the Dolomites Phase 2 clinical trial, 0.065%, was evaluated together with a higher 0.1% concentration of NCX 470.
  • The 0.1% dose of NCX 470 was selected in the adaptive stage of the Mont Blanc trial and enabled the second part of the Mont Blanc Phase 3 trial and the start of Denali Phase 3 trial.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.

Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial

Retrieved on: 
Thursday, March 4, 2021
Ophthalmology, NicOx, Chemical compounds, Drugs, Prostaglandins, Triols, Cyclopropanes, Latanoprost, Glaucoma, Eye drop, Ocular hypertension

Nicoxs lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog licensed exclusively to Ocumension Therapeutics for the Chinese, Korean and South East Asian markets.

Key Points: 
  • Nicoxs lead clinical product candidate, NCX 470, is a novel nitric oxide (NO)-donating prostaglandin analog licensed exclusively to Ocumension Therapeutics for the Chinese, Korean and South East Asian markets.
  • Dr. Jos Boyer, Interim Head of R&D at Nicox, said: This approval allows us to initiate Chinese patients in the Denali trial on schedule.
  • Denali, the second Phase 3 trial of NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, was initiated in the U.S. on November 9, 2020.
  • Denali is a 3-month trial evaluating the safety and efficacy of NCX 470 ophthalmic solution, 0.1% versus latanoprost ophthalmic solution, 0.005% and will also include a long-term safety extension.

Bausch Health Announces Vyzulta® (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea

Retrieved on: 
Tuesday, February 9, 2021
Chemical compounds, Drugs, Ophthalmology, Prostaglandins, Triols, Cyclopropanes, Blindness, Lomb, Glaucoma, Latanoprostene bunod, Ocular hypertension, Intraocular pressure

Bausch + Lomb remains focused on bringing forward innovative eye health treatment options to help address unmet medical needs around the world.

Key Points: 
  • Bausch + Lomb remains focused on bringing forward innovative eye health treatment options to help address unmet medical needs around the world.
  • VYZULTA is now approved in nine markets, including Argentina, Canada, Colombia, Hong Kong, Mexico, South Korea, Taiwan, Ukraine and the United States.
  • VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see.

Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study

Retrieved on: 
Wednesday, January 13, 2021
Medical devices, Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, Organic compounds, Chemical compounds, Chemistry, Prostaglandins, Triols, Cyclopentanes, Travoprost, IOP, Idose

Once all travoprost is released, the iDose TR was designed to be removed and replaced with a new iDose TR, thus offering an alternative to daily eye drop treatment.

Key Points: 
  • Once all travoprost is released, the iDose TR was designed to be removed and replaced with a new iDose TR, thus offering an alternative to daily eye drop treatment.
  • All IOP analyses were calculated using all IOP observations over 24 months weighted equally with no imputations for protocol-mandated medications.
  • Subjects who had been on a single pre-study IOP-lowering medication at the screening visit had greater average IOP reduction over 24 months on iDose TR versus the pre-study IOP-lowering eye drops.
  • The 12-month iDose TR Phase 3 trial results are expected to support Glaukos NDA submission in 2022 and the company is now targeting FDA approval for iDose TR in 2023.

Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico

Retrieved on: 
Wednesday, January 6, 2021
NicOx, Prostaglandins, Triols, Chemical compounds, Organic compounds, Chemistry

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that an affiliate of its licensee, Bausch + Lomb, has launched VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Mexico.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that an affiliate of its licensee, Bausch + Lomb, has launched VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Mexico.
  • First approved by the U.S. Food and Drug Administration in late 2017, VYZULTA is now commercialized in the United States, Canada, Argentina and Mexico.
  • Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones payments.
  • Nicoxs lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.

Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

Retrieved on: 
Friday, December 11, 2020
Chemical compounds, Drugs, Organic compounds, Prostaglandins, Cyclopropanes, Latanoprost, Triols, Blindness, Diabetes, Glaucoma, Diabetic nephropathy

The razuprotafib once-daily (QD) dose group did not show a statistically significant improvement at Day 28.

Key Points: 
  • The razuprotafib once-daily (QD) dose group did not show a statistically significant improvement at Day 28.
  • The study was designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib as an adjunct to standard of care latanoprost.
  • The primary endpoint of the study was mean diurnal IOP at 28 days in the razuprotafib treated groups compared to the latanoprost monotherapy group.
  • Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy.

Information update - LEO Pharma Inc. is withdrawing the drug Picato (Ingenol mebutate), used to treat skin lesions, due to the potential increased risk of skin cancer

Retrieved on: 
Tuesday, October 27, 2020
Organic compounds, Chemical compounds, Chemistry, Cyclopropanes, Diterpenes, Ingenol mebutate, Ketones, Triols

What to do: Stop your treatment and talk to your healthcare professional about other treatment options.

Key Points: 
  • What to do: Stop your treatment and talk to your healthcare professional about other treatment options.
  • Monitor your skin for signs or symptoms of skin cancer.
  • At Health Canada's request, LEO Pharma Inc. is withdrawing Picato from the Canadian market.
  • On October 26, 2020, LEO Pharma Inc. initiated the recall of Picato from the Canadian market.

Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial

Retrieved on: 
Monday, October 26, 2020
Chemical compounds, Organic compounds, Health, Prostaglandins, Triols, Cyclopropanes, Latanoprost, Glaucoma, Clinical trial, Ocular hypertension, Sodium-calcium exchanger, NicOx

NCX 470 development remains on track, with first results from the Mont Blanc trial expected in Q4 2021.

Key Points: 
  • NCX 470 development remains on track, with first results from the Mont Blanc trial expected in Q4 2021.
  • Initiation of Chinese sites in this trial will be essential in preparing the way for Denali, the second Phase 3 trial with NCX 470, which will include a larger number of Chinese patients.
  • The NCX 470 Mont Blanc Phase 3 clinical trial is a 3-month trial to evaluate the safety and efficacy of NCX 470 ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
  • The Mont Blanc trial was initiated in the U.S. in June 2020 and top-line results are currently expected in Q4 2021.